The efficacy and safety of cefovecin in the treatment of naturally occurring bacterial infections of skin and soft tissues in dogs was evaluated in patients presented to veterinary clinics in Japan. Patients were treated with either cefovecin (8 mg/kg bodyweight as a single subcutaneous injection) or with orbifloxacin (5 mg/kg bodyweight by oral administration once daily for seven consecutive days) according to a randomised design. Prior to treatment, the predominant pathogens identified were Staphylococcus intermedius, Staphylococcus aureus and Proteus mirabilis. The MIC 90 values of cefovecin and orbifloxacin, respectively, for isolates of these three pathogens were: 0.12 µg/ml and 0.5 µg/ml for S. intermedius; 1 µg/ml and 1 µg/ml for S. aureus; 0.5 µg/ml and 4 µg/ml for P. mirabilis. The response to treatment was assessed using clinical scores recorded according to an index for the clinical signs of skin infection. The clinical scores recorded pretreatment and at 7 and 14 days post-treatment were used to calculate an improvement ratio for each animal and dogs were categorised as either "cured", "improved" or "failed" according to the degree of improvement observed. Animals categorised as "cured" or "improved" were considered a clinical success. For cefovecin, the clinical success at Day 7 post-treatment was 63.8% (37 out of 58 animals) and at Day 14, 87.5% (49 out of 56 animals); for orbifloxacin clinical success at Day 7 and Day 14 post-treatment was 44.4% (24 out of 54 animals) and 73.3% (33 out of 45 animals), respectively. No adverse events attributable to cefovecin were observed during the study period and no injection site abnormalities were noted in any animals. The results demonstrated that when administered subcutaneously once at a dose of 8 mg/kg bodyweight, cefovecin was effective and safe in the treatment of skin and soft tissue infections in dogs.
Introduction
Diseases of the skin are among the most important and frequently presented conditions in companion animal veterinary practice 18) . According to official statistics, dogs presenting with skin disease amounted to 19 .2% of the total number of canine patients during surveillance conducted in Japan during 2001 15) . The most common bacterial species isolated from the lesions associated with skin and soft tissue infections in dogs is Staphylococcus intermedius 3, 5, 14, 22, 23) . Although S. intermedius is among the resident flora of the dog's nasal and oropharyngeal mucosa, and anus 2, 6, 7, 23) , it spreads to the skin through grooming activity 12) and may become pathogenic f o l l o w i n g d i s r u p t i o n s i n t h e s k i n -s u r f a c e microenvironment mostly caused by some underlying cutaneous, metabolic, or immunological abnormality. Secondary infection of skin lesions with Proteus spp., Pseudomonas spp., and Escherichia coli is common 12, 18) . Current scientific literature suggests that superficial pyoderma requires three to four week of antimicrobial therapy, whereas the duration of treatment for deep pyoderma should be from 4 to 6 weeks and, on occasions, longer 4) . Generally, antimicrobials for the treatment of skin infections are available for administration as oral tablets and, due to their elimination half-lives, such products may have to be administered orally up to three times a day.
Reviews of antimicrobial therapy often recommend the use of cephalosporins for the treatment of canine skin infections and this is based on the excellent safety profile and efficacies of such products 16, 18) . Cefovecin is a novel extended spectrum cephalosporin developed for veterinary use 19) . It is formulated as an injectable aqueous solution containing 80 mg/ml cefovecin sodium for use in dogs and cats. Following subcutaneous administration, cefovecin has a long elimination half-life (5.5 days in dogs) and cefovecin concentrations in interstitial tissue fluid remains above the MIC 90 value for S. intermedius for approximately 14 days 20) . For clinical presentations where it is appropriate, this pharmacokinetic/ pharmacodynamic profile allows prolonged therapeutic efficacy to be maintained through repeated injections administered at 14-day intervals. It is generally acknowledged that, in the domestic environment, there are significant potential risks of non-compliance with the prescribed dosing regimen associated with oral medications which require daily administration 1, 10) . The mode of administration and duration of efficacy of cefovecin avoids such risks. With those considerations in mind, the efficacy and safety of cefovecin (administered as a single subcutaneous injection) was compared with that of a positive control, orbifloxacin (administered orally for seven consecutive days in accordance with the manufacturer's label instructions), for the treatment of bacterial skin and soft tissue infections in dogs.
Materials and Methods
The study was conducted according to a common protocol at 21 The clinical outcome for each animal, reflecting the degree of resolution of the clinical signs (erythema, exudate, pustule(s) and swelling) following treatment, was then categorised as "cured", "improved" or "failed" using the improvement ratio calculated as described above. The three categories for clinical outcome were defined as follows:
Improvement ratio for clinical assessment score >85%. "Improved": Improvement ratio for clinical assessment score ≥70% and ≤85%. "Failed":
Improvement ratio for clinical assessment score <70%.
Cases categorised as either "cured" or "improved" were Pustule(s) A small, elevated circumscribed 1: Mild = The intensity/density of the abnormality is low and pus-containing lesion of the skin only a small area of the animal's body is affected 2: Moderate = The abnormality is of great intensity/density over a small area or is of lesser intensity/density but affects a large area of the animal's body 3: Severe = The abnormality is of great intensity/density and covers a large area of the animal's body considered to have been a "clinical success". Within treatment groups, the improvement ratios for those cases considered to be "cured" and "improved" were combined and Fisher's Exact Test was used to compare the two treatment groups at the 5% level of statistical significance. Samples for microbiological examination were obtained from the site of infection prior to treatment on Day 0. Where possible, bacterial identification was performed at the species level based on morphology, gram stain, growth characteristics, standard individual biochemical tests or commercial identification kits.
Antimicrobial susceptibility testing of the pre-treatment isolates was undertaken at a single laboratory in accordance with the Clinical and Laboratory Standards Institute (formerly National Committee of Clinical Laboratory Standards) guidelines 17) in order to determine minimum inhibitory concentrations (MICs) for cefovecin and orbifloxacin. MICs were determined by broth microdilution using customized microdilution plates (Sensititre ® Microdilution Plates, Trek Diagnostic Systems Ltd., East Grinstead, UK) provided by Pfizer Animal Health.
Results

Animal details
A total of 116 dogs were enrolled in the study. Of these, one dog was excluded from all assessments of efficacy and safety because no pathogen(s) were isolated from the pre-treatment microbiological sample and therefore it did not meet the requirements of the study protocol. One hundred and fifteen cases were evaluated for safety; of these, 59 dogs were treated with cefovecin and 56 dogs were treated with orbifloxacin. Assessments of efficacy at Day 7 and Day 14 post-treatment were based on data from 112 and 101 cases, respectively ( Table 2 ). Details of the number, gender, breed (pure or mixed), age and bodyweight of dogs participating in the study are summarised in Table 3 . Of the 115 dogs which participated in the assessment of safety, 60 were male and 55 were females and the mean age and bodyweight of these dogs at the time of enrolment was 6.3 years and 10.7 kg, respectively.
Evaluation of efficacy
Prior to treatment, among the 115 cases with data suitable for evaluation, 71.3% of dogs were diagnosed with superficial pyoderma (of these, 72.9% were treated a) One dog was excluded from all assessments of efficacy and safety because no pathogens were isolated from the pre-treatment microbiology sample. b) Dogs which did not attend at the clinic(s) for post-treatment assessments within the time limits required by the protocol were excluded from all assessments of efficacy. with cefovecin and 69.6% with orbifloxacin), 9.6% were diagnosed with deep pyoderma (10.2% cefovecin; 8.9% orbifloxacin), 13.0% were diagnosed with abscesses (13.6% cefovecin; 12.5% orbifloxacin) and 6.1% were diagnosed with a wound(s) (3.4% cefovecin; 8.9% orbifloxacin) ( Table 4 ). The distribution of clinical scores prior to treatment was similar for animals in both treatment groups; for dogs treated with cefovecin 23.7% had low scores (1-4), 62.7% had medium scores (5-8), and 13.6% had high scores (9-12); for dogs treated with orbifloxacin the distribution was 28.6%, 51.8%, and 19.6%, respectively ( Table 5) .
Following treatment, at both Day 7 and Day 14, the distribution of clinical scores was shifted in both treatment groups with more dogs having low scores and some dogs assessed as having zero clinical scores. This tendency was more marked in the group treated with cefovecin than in the group treated with orbifloxacin. At Day 7, for dogs treated with cefovecin, the percentage of animals with zero, low, medium or high clinical scores was 25.9%, 69.0%, 5.2%, and 0.0, respectively, and for dogs treated with orbifloxacin the distribution of scores was 14.8%, 74.1%, 7.4% and 3.7%, respectively. At Day 14, for dogs treated with cefovecin, the percentage of animals with zero, low, medium or high clinical scores was 73.2%, 25.0%, 1.8%, and 0.0, respectively, and for dogs treated with orbifloxacin the distribution of scores was 53.3%, 37.8%, 4.4% and 4.4%, respectively (Table 5) .
Of the dogs which were treated with cefovecin, 34.5% (20 out of 58 cases) were considered to have been "cured" at Day 7 (i.e. where the calculated improvement ratio for their pre and post-treatment clinical scores was > 85%) and for dogs treated with orbifloxacin, 22.2% (12 out of 54 cases) were considered to have been "cured" at Day 7. At Day 14, 82.1% of dogs treated with cefovecin (46 out of 56 cases) were considered to be "cured" compared with 53.3% for dogs treated with orbifloxacin (24 out of 45 cases).
At Day 7, of the dogs treated with cefovecin, 63.8% (37 out of 58 cases) were considered to be clinical successes (i.e. where the calculated improvement ratio for their pre and post-treatment clinical scores was ≥ 70% and which were categorised as "cured" or "improved") and this had increased to 87.5 (49 out of 56 cases) at Day 14. For dogs treated with orbifloxacin, the percentage of cases considered to be clinical successes at Day 7 was 44.4% (24 out of 54 cases) and at Day 14, 73.3% (33 out of 45 cases) ( Table 6 ). Statistical analysis indicated that there was no statistical difference in the rate of clinical success between the two treatment groups (P = 0.0794). 
Evaluation of safety
No adverse events attributable to cefovecin were observed in any animal during the study period and no injection site abnormalities were noted in any animals.
Microbiological data
A total of 169 bacterial isolates were obtained and identified from the microbiological samples collected prior to treatment. The predominant pathogens identified were S. intermedius, S. aureus, and P. mirabilis.
The MIC 90 values for cefovecin and orbifloxacin for S. intermedius were 0.12 µg/ml (range: 0.06-0.25 µg/ml) and 0.5 µg/ml (range: 0.25-0.5 µg/ml), respectively; for S. aureus, 1 µg/ml (range: 0.06-2 µg/ml) and 1 µg/ml (range: 0.25-2 µg/ml), respectively, and for P. mirabilis, 0.5 µg/ml (range: 0.12-0.5 µg/ml) and 4 µg/ml (range: 0.5-4 µg/ml), respectively (Table 7) .
Discussion
This study confirmed that, when compared with daily administration of a potent fluoroquinolone, orbifloxacin, a single administration of cefovecin was effective in the treatment of naturally occurring bacterial skin infections in dogs. Orbifloxacin is recognised as effective in the treatment of bacterial skin infections in dogs and cats 9, 12) .
In Japan, the oral tablet formulation(s) of orbifloxacin is approved for treatment of canine bacterial skin infections a) The clinical outcome for each animal was categorised according to the degree of resolution of the clinical signs (erythema, exudate, pustule(s) and swelling) following treatment, based on the improvement ratio calculated from the clinical scores recorded at each assessment point. The three categories for clinical outcome were defined as follows:
"Cured": Improvement ratio for clinical assessment score > 85%.
"Improved": Improvement ratio for clinical assessment score ≥ 70% and ≤ 85%.
"Failed": Improvement ratio for clinical assessment score < 70%. b) For dogs categorised as "cured" or "improved", treatment was deemed to have been effective and these cases were considered to have been clinical successes.
c) For those dogs considered to have been clinical successes, a between treatment statistical comparison was performed using Fisher's Exact test at the 5% level of statistical significance. The objective of the sponsor in conducting this study was to support regulatory approval of cefovecin for the Japanese market. The authors acknowledge that the efficacy results presented in this paper do not support any suggestion that superficial or deep pyoderma infections can, in general, be successfully treated with less than 14 days of antimicrobial therapy. The clinical signs observed in the majority of cases enrolled in this study were mild or moderate in severity, and consequently high rates of efficacy were observed despite the relatively short duration of treatment permitted within the study design.
The bacterial species identified during this study were typical of those described for canine skin infections, with S. intermedius recorded as the most frequently isolated species. Consequently the bacteriological infections seen in cases enrolled in the study may be considered as typical of the presentations seen in normal clinical practice. The excellent in vitro activity of cefovecin has been demonstrated in recent work with clinical isolates from Europe and the United States across an extended spectrum of both gram-positive and gram-negative pathogens including S. intermedius, E. coli, and Pasteurella multocida 19) . In this study, the susceptibility of the predominant pathogens (S. intermedius, S. aureus, and P. mirabilis) was also high and the MIC data were comparable with earlier studies 19) .
First generation cephalosporins, such as cephalexin and cefadroxil, are also effective in the treatment of canine skin infections 8) and generic products licensed for use in humans are frequently used in Japanese veterinary practice. However the daily oral dosing regimen associated with these drugs frequently presents difficulties in terms of dosing compliance in the domestic environment. A single injection of cefovecin provides a fourteen day duration of efficacy and thus offers the benefit of eliminating dosing non-compliance which can be a potential cause of treatment failure in canine bacterial skin infections.
In conclusion, the study reported in this paper demonstrated that cefovecin is effective and safe in the treatment of canine skin infections when administered once subcutaneously at a dosage of 8 mg/kg bodyweight.
